Shield Diagnostics (UK) awarded 510(k) for Diastat kits:
This article was originally published in Clinica
Shield Diagnostics (UK) has received 510(k) clearance from the US FDA for its anti-Tg and anti-TPO Diastat kits. Both kits use ELISA technology to detect antibodies in human plasma or serum. Total assay time is two hours and the common reagents are interchangeable so both thyroid tests can be performed on the same patient sample dilution, says Shield. All 19 of Shield's Diastat products are now registered with the FDA.
You may also be interested in...
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.